Endometriosis Treatment & Management
- Author: Dharmesh Kapoor, MBBS, MD, MRCOG; Chief Editor: Michel E Rivlin, MD more...
Approach Considerations
The dependence of endometriosis on the woman's cyclic production of menstrual cycle hormones provides the basis for medical therapy. Medications currently recommended include gonadotropin-releasing hormone (GnRH) agonists, progestins, oral contraceptive pills, and androgens. Each of these interrupts the normal cyclic production of reproductive hormones. There are some data supporting the use of aromatase inhibitors for refractory or recurrent endometriosis.
Medical vs surgical therapy
In women who wish to preserve their reproductive potential, the rates of recurrent pain symptoms are 44% with surgical management and 53% with medical management.[50, 51]
Endometriosis and subfertility
Peritubal and periovarian adhesions can interfere mechanically with ovum transport and contribute to subfertility. Peritoneal endometriosis has been postulated to contribute to subfertility by interfering with tubal motility, folliculogenesis, and corpus luteum function. Aromatase is believed to increase the prostaglandin E levels via increase in the cyclooxygenase-2 (COX-2) expression. Endometriosis may also cause subfertility by causing more sperm binding to the ampullary epithelium, thereby affecting sperm-endosalpingeal interactions.[52]
Medical treatment of minimal or mild endometriosis has not been shown to increase pregnancy rates.[53] Moderate to severe endometriosis should be treated surgically.[54]
Other options for achieving pregnancy include intrauterine insemination, superovulation, and in vitro fertilization. In a case-controlled study, pregnancy rates with intracytoplasmic sperm injection were not affected by the presence or extent of endometriosis.[55] Furthermore, other analyses have shown improvement with in vitro fertilization pregnancy rates with pretreatment of stage 3 and 4 endometriosis with gonadotropin-releasing hormone (GnRH) agonists.
Interval treatment
Some authorities believe that endometriosis should be suppressed prophylactically by continuous combined oral contraceptives, GnRH analogs, medroxyprogesterone, or danazol in order to cause regression of asymptomatic disease and enhance subsequent fertility. However, according to a Cochrane review, no benefit is derived from ovulation suppression in subfertile women with endometriosis who wish to conceive.[56]
A Cochrane review of interventions in women with endometriomata (cysts of endometriosis in the ovaries) before the use of assisted reproductive technology (ART) identified 4 trials with 312 participants could reach no conclusions regarding interventions for the management of endometriomata in women undergoing ART.[57] Further trials are required.
Surgical ablation of asymptomatic endometriosis has also been shown to improve fecundity rates on a 3-year follow-up.[54]
Recurrent pregnancy loss
Based on results from controlled prospective studies, no evidence indicates that endometriosis is associated with recurrent pregnancy loss, and no evidence indicates that medical or surgical treatment of endometriosis reduces the spontaneous abortion rate.[58]
Hormonal Therapy
The dependence of endometriosis on the woman's cyclic production of menstrual cycle hormones provides the basis for medical therapy. Thus, combination oral contraceptive pills (COCPs), danazol, progestational agents, and gonadotropin-releasing hormone (GnRH) analogues form the mainstay of medical therapy. All these treatments have similar clinical efficacy in terms of reduction in pain-related symptoms and duration of relief. See Medications.
Nonsteroidal anti-inflammatory agents (NSAIDS) have not been shown to have any benefit in placebo-controlled trials.[59] In a systematic review, aromatase inhibitors were shown to have promising results for pain relief when combined with either progestins, COCPs , or GnRH analogues.[60] However, the authors concluded that the strength of this inference was limited due to lack of sizeable trials.[60]
Combination oral contraceptive pills
COCPs act by ovarian suppression and continuous progestin administration. Initially, a trial of continuous or cyclic COCPs should be administered for 3 months. With pain relief, this treatment is continued for 6-12 months. Pregnancy rates following discontinuation of the pill are 40-50%. This applies to a population unselected for stage and fertility status of the disease. Although few choices are available among individual formulations, note that the long-term efficacy of multiphasic preparations remains unproven.
Continuous noncyclical administration of COCPs, omitting the placebo menstrual tablets, for 3-4 months helps avoid any menstruation and associated pain. A study by Guzick et al examined a head-head-to-head comparison of Lupron and continuous oral contraceptives for the treatment of endometriotic pelvic pain; both were found to be equally effective.[61]
Women with endometriosis are at increased risk of epithelial ovarian cancer, and COCPs are believed to protect against this.[62]
Progestational agents
All progestational agents act by decidualization and atrophy of the endometrium.
Medroxyprogesterone acetate has proven efficacy in pain suppression in both the oral and injectable depot preparations.[63, 64] Oral doses of 10-20 mg/d can be administered continuously. The time to resumption of ovulation is longer and variable with depot preparations. Adverse effects include weight gain, fluid retention, depression, and breakthrough bleeding.
Megestrol acetate has been used in doses of 40 mg with similarly good results.[65]
The levonorgestrel intrauterine system (LNG-IUS) has been shown to reduce endometriosis-associated pain.[66] When inserted at the time of laparoscopic surgery, it has been found to reduce the recurrence of dysmenorrhea by 35%.[67]
Gonadotropin-releasing hormone analogues
GnRH analogues produce a hypogonadotrophic-hypogonadic state by downregulation of the pituitary gland. Goserelin and leuprolide acetate are the commonly used agonists. Efficacy is limited to pain suppression, and fertility rates may show no improvement.[68]
Winkel et al have claimed that GnRH therapy may lead to improvement in pain associated with endometriosis in 85-100% of women.[69] Furthermore, the pain relief is believed to persist for 6-12 months after cessation of treatment.
Treatment is usually restricted to monthly injections for 6 months. Loss of trabecular bone density caused by GnRH is restored by 2 years after cessation of therapy.[70] Other prominent adverse effects include hot flashes and vaginal dryness.
Add-back therapy and empiric therapy
Much interest has been shown in whether estrogen/progestin "add-back" therapy should be instituted to prevent osteoporosis and hypoestrogenic symptoms. Hormone replacement therapy preparations, progestins, tibolone maleate, and bisphosphonates have all been shown to be effective.[71, 72, 73, 74] Add-back therapy has been shown to prevent loss in bone density and to relieve vasomotor symptoms without reducing the efficacy of GnRH regimens. GnRH agonists have been used for 12 months with norethindrone add-back therapy with good results.[75]
A clinical trial has shown that a 3-month empiric course of GnRH, based on a diagnostic algorithm without definitive laparoscopic diagnosis, is efficacious.[76] However, long-term effects of GnRH analogues on bone density in this population remain unproven. Therefore, add-back therapy remains the standard of care while the patient is on GnRH treatment. Also, empiric treatment without a firm diagnosis could result in unnecessary treatment in patients with chronic pelvic pain, whose condition could be due to other causes. In Ling's study, 13% of subjects were shown to not have endometriosis.[76]
GnRH therapy has also been proven to relieve the pain and bleeding associated with extrapelvic distant endometriosis.[77]
GnRH analogues vs danazol
A Cochrane review comparing GnRH analogues with danazol treatment showed no difference in improvement of dysmenorrhea, dyspareunia, pelvic pain, or pelvic tenderness.[78] Likewise, no difference in retrospective American Fertility Society (rRAFS) score was found at approximately 24 weeks' follow-up. In contrast, studies that evaluated total pain resolution showed greater benefit from GnRH analogues compared with danazol. Side-effect profiles differed, with greater frequency of hot flushes and vaginal dryness with GnRH analogues, whereas danazol treatment resulted in a greater frequency of weight gain, acne, and headaches.
Danazol
Danazol acts by inhibiting the midcycle follicle-stimulating hormone (FSH) and luteinizing hormone (LH) surges and preventing steroidogenesis in the corpus luteum. It is the most extensively studied agent for endometriosis.
Danazol has been shown to be as effective as any of the newer agents, but with a higher incidence of adverse effects. Its androgenic manifestations include oily skin, acne, weight gain, deepening of the voice, and facial hirsutism. Hypoestrogenic features due to danazol include emotional lability, hot flashes, vaginal dryness, and reversible breast atrophy.
The recommended dose is 600-800 mg/d. However, smaller doses have been used with success.[79, 80] In a small study of 21 patients, vaginal danazol (200 mg/d) was successful in relieving endometriosis-associated pain.[81]
Barrier contraception and ERT
Because of the possibility of virilizing changes in a female fetus, additional barrier contraception must be used while on danazol therapy.
The evidence for estrogen replacement therapy (ERT) in women with postsurgical menopause for treatment of endometriosis is unclear at the present time.[82]
Surgical Intervention
Surgical care can be broadly classified as conservative when reproductive potential is retained, semiconservative when reproductive ability is eliminated but ovarian function is retained, and radical when the uterus and ovaries are removed. Age, desire for future childbearing, and deterioration of quality of life are the main considerations when deciding on the extent of surgery.
Surgical efforts are aimed at removal of the endometrial implants and correction of anatomic distortions. Implants can be ablated using either laser energy or electrosurgical techniques.
Resection of the implants and adjacent peritoneum is considered the treatment of choice by some authors. A radical surgical approach involves total hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO). This is generally reserved for women who have completed their family or for women with severely disabling pain that is unresponsive to more conservative approaches.
Conservative Surgery
With conservative surgery, the aim is to destroy visible endometriotic implants and lyse peritubal and periovarian adhesions that are a source of pain and may interfere with ovum transport. The laparoscopic approach is the method of choice for treating endometriosis conservatively.[83, 84]
Ablation can be performed with laser or electrodiathermy. Overall, the recurrence rate is 19% and is similar for all techniques.[85] Laparoscopic ablative surgery with bipolar diathermy or laser for endometriomas was shown to be effective for relieving pelvic pain in 87% of patients.[86]
Drainage vs laparoscopic cystectomy
Ovarian endometriomas can be treated by drainage or cystectomy. Laparoscopic cystectomy was found to yield better pain relief and pregnancy rates than drainage.[87, 88] Medical therapy with gonadotropin-releasing hormone (GnRH) agonists reduces the size of the cyst but does not influence pain relief.[89]
Ablation vs diagnostic laparoscopy
In the short term, the absolute benefit for women undergoing surgical ablation of endometriosis is 30-40% over women having only diagnostic laparoscopy. This benefit is reduced over time, and the reoperation rate is as high as 50%.[90] In cases of rectovaginal endometriosis, significant short-term pain relief was reported by up to 80%, but at 1-year follow-up, 50% required analgesics or hormones for pain relief. During postoperative treatment, GnRH analogues resulted in significantly reduced pain scores in women who received treatment for 6 months.
Tubal flushing with oil-soluble media has been shown to improve pregnancy rates in women with endometriosis-associated infertility.[91]
Presacral neurectomy and laparoscopic uterine nerve ablation
Presacral neurectomy is used to relieve severe dysmenorrhea. The nerve bundles are transected at the level of the third sacral vertebra, and the distal ends are ligated. Vascular injury to the middle sacral artery and vein is a potential complication, and some authors advocate prophylactic ligation. Also, constipation is a long-term adverse effect (94%) of this procedure and should be considered while deciding whether to perform this procedure.
Nodularity of the uterosacral ligaments may contribute to dyspareunia and low back pain. The transmission of neural pathways is via the Lee-Frankenhäuser plexus. Laparoscopic uterine nerve ablation (LUNA) is performed to interrupt the pain fibers. Potential complications of this procedure include uterine prolapse and pelvic denervation. A systematic review of trials of LUNA found no advantage in terms of pain relief when compared to placebo.[92] However, when combined with laparoscopic ablation, LUNA significantly reduced pain attributed to endometriosis.[50] In patients with subfertility, tissue ablation significantly increased the cumulative pregnancy rate.[54] A Cochrane review failed to show any benefit from either LUNA or presacral neurectomy.[93]
Postoperative adjunctive hormone therapy
For patients with mild disease, postoperative adjunctive hormonal treatment has been shown effective in reducing pain but has no impact on fertility. GnRH analogues, danazol, and medroxyprogesterone have all been found to be useful for this indication.[94, 95, 96, 97] However, for severe endometriosis, the efficacy of preoperative or postoperative hormonal treatment has not yet been established.
Semiconservative Surgery
The indication for this semiconservative surgery is mainly in women who have completed their childbearing, are too young to undergo surgical menopause, and are debilitated by the symptoms. Such surgery involves hysterectomy and cytoreduction of pelvic endometriosis.
Ovarian endometriosis can be removed surgically, because one tenth of functioning ovarian tissue is all that is needed for hormone production. Patients who undergo hysterectomy with ovarian conservation have a 6-fold higher rate of recurrence compared to women who undergo oophorectomy.[98]
Medical therapy in women who have completed childbearing is equally efficacious for symptom suppression.[99, 51, 100]
Radical Surgery
Radical surgery involves total hysterectomy with bilateral oophorectomy (TAH-BSO) and cytoreduction of visible endometriosis. Adhesiolysis is performed to restore mobility and normal intrapelvic organ relationships.
Ureteric obstruction may warrant surgical release or excision of a damaged segment. Bowel obstruction may require a resection anastomosis or a wedge resection if the obstruction is confined to the anterior rectosigmoid.
Endometriosis may recur in 15% of women after extirpative surgery, irrespective of whether estrogen-replacement therapy (ERT) is given postoperatively.[101] ERT can be instituted safely immediately after surgery, especially in younger women who face the prospect of accelerated bone loss and vasomotor symptoms.[101, 102] No trials have reported the use of estrogen plus progestin therapy with respect to estrogen therapy alone postoperatively. However, theoretically, the addition of a continuous progestin could decrease the regrowth of endometriosis.
Prevention
No current methods of prevention are known. Some evidence suggests that rapid and aggressive medical or surgical therapy can arrest progression, especially when the disease is caught in the early (minimal to mild) stages.
Early and prolonged use of oral contraceptive pills, pregnancy, and breast-feeding seem to afford some degree of protection against this disease.
Consultations
Treat patients with endometriosis in consultation with a physician experienced in the diagnosis and management of this condition and its complications, such as an obstetrician/gynecologist. If extensive disease is present, specialists in reproductive endocrinology, urology, colorectal surgery, and even gynecologic oncology may be required.
Any postpubertal patient going to the operating room for acute or chronic pelvic/abdominal pain could have endometriosis, therefore, consultation with a physician having the experience to recognize, diagnose, and treat this disease is prudent. Conservation of future fertility may be dependent on the conservative and meticulous surgical approach of an expert reproductive surgeon.
Long-Term Monitoring
If the presumptive diagnosis is endometriosis and follow up is arranged, pain management can include the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or narcotic analgesics. Start patients with classic symptoms of endometriosis and no reason to suspect another cause on medical therapy. Surgical diagnosis is not always required.
Lack of rapid response (within 1-2 cycles) to medical therapy should prompt a search for other causes of the patient's symptoms. Consider diagnostic laparoscopy if it has not been performed previously.
In patients who underwent surgery for endometriosis (or had endometriosis discovered during surgery for another indication), consider adjuvant medical treatment (see Hormonal Therapy). At a minimum, place these patients on oral contraceptive pills until they are ready to conceive.
Endometriosis is progressive and can result in chronic pain and infertility. Gynecologic follow-up is advised.
Pediatric patients
Although most pediatric patients are not currently interested in becoming pregnant, subsequent fertility is likely a major concern. Evidence is mounting that early and aggressive therapy may alter the course of this disease.[103] Investigate moderate to severe dysmenorrhea that is unresponsive to NSAIDs and pelvic pain persisting longer than 3 months.
Lobo RA. Endometriosis: etiology, pathology, diagnosis, management. In: Comprehensive Gynecology. Philadelphia, PA: Mosby; 5th ed:2007:chap 19.
Shepard MK, Mancini MC, Campbell GD Jr, George R. Right-sided hemothorax and recurrent abdominal pain in a 34-year-old woman. Chest. Apr 1993;103(4):1239-40. [Medline].
Markham SM, Carpenter SE, Rock JA. Extrapelvic endometriosis. Obstet Gynecol Clin North Am. Mar 1989;16(1):193-219. [Medline].
Jubanyik KJ, Comite F. Extrapelvic endometriosis. Obstet Gynecol Clin North Am. Jun 1997;24(2):411-40. [Medline].
ACOG practice bulletin. Medical management of endometriosis. Number 11, December 1999 (replaces Technical Bulletin Number 184, September 1993). Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet. Nov 2000;71(2):183-96. [Medline].
Buchweitz O, Poel T, Diedrich K, Malik E. The diagnostic dilemma of minimal and mild endometriosis under routine conditions. J Am Assoc Gynecol Laparosc. Feb 2003;10(1):85-9. [Medline].
Liu DT, Hitchcock A. Endometriosis: its association with retrograde menstruation, dysmenorrhoea and tubal pathology. Br J Obstet Gynaecol. Aug 1986;93(8):859-62. [Medline].
Kruitwagen RF, Poels LG, Willemsen WN, de Ronde IJ, Jap PH, Rolland R. Endometrial epithelial cells in peritoneal fluid during the early follicular phase. Fertil Steril. Feb 1991;55(2):297-303. [Medline].
Scott RB, Te Linde RW, Wharton LR Jr. Further studies on experimental endometriosis. Am J Obstet Gynecol. 1953;66:1082.
D'Hooghe TM, Bambra CS, Raeymaekers BM, Koninckx PR. Increased prevalence and recurrence of retrograde menstruation in baboons with spontaneous endometriosis. Hum Reprod. Sep 1996;11(9):2022-5. [Medline].
Mathur S, Peress MR, Williamson HO, Youmans CD, Maney SA, Garvin AJ, et al. Autoimmunity to endometrium and ovary in endometriosis. Clin Exp Immunol. Nov 1982;50(2):259-66. [Medline]. [Full Text].
Acién P, Velasco I, Gutiérrez M, Martínez-Beltrán M. Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings. Fertil Steril. Jul 2007;88(1):32-8. [Medline].
Matsuzaki S, Canis M, Pouly JL, Wattiez A, Okamura K, Mage G. Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertil Steril. Nov 2004;82(5):1309-15. [Medline].
Wölfler MM, Nagele F, Kolbus A, Seidl S, Schneider B, Huber JC, et al. A predictive model for endometriosis. Hum Reprod. Jun 2005;20(6):1702-8. [Medline].
Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril. Dec 1999;72(6):961-9. [Medline].
Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril. May 2004;81(5):1395-8. [Medline].
Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. Feb 2004;81(2):290-6. [Medline].
Suginami H. A reappraisal of the coelomic metaplasia theory by reviewing endometriosis occurring in unusual sites and instances. Am J Obstet Gynecol. Jul 1991;165(1):214-8. [Medline].
Metzger DA, Lessey BA, Soper JT, McCarty KS Jr, Haney AF. Hormone-resistant endometriosis following total abdominal hysterectomy and bilateral salpingo-oophorectomy: correlation with histology and steroid receptor content. Obstet Gynecol. Nov 1991;78(5 Pt 2):946-50. [Medline].
Schrodt GR, Alcorn MO, Ibanez J. Endometriosis of the male urinary system: a case report. J Urol. Nov 1980;124(5):722-3. [Medline].
Ueki M. Histologic study of endometriosis and examination of lymphatic drainage in and from the uterus. Am J Obstet Gynecol. Jul 1991;165(1):201-9. [Medline].
Wheeler JM. Epidemiology of endometriosis-associated infertility. J Reprod Med. Jan 1989;34(1):41-6. [Medline].
Rawson JM. Prevalence of endometriosis in asymptomatic women. J Reprod Med. Jul 1991;36(7):513-5. [Medline].
Strathy JH, Molgaard CA, Coulam CB, Melton LJ 3rd. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril. Dec 1982;38(6):667-72. [Medline].
Verkauf BS. Incidence, symptoms, and signs of endometriosis in fertile and infertile women. J Fla Med Assoc. Sep 1987;74(9):671-5. [Medline].
Carter JE. Combined hysteroscopic and laparoscopic findings in patients with chronic pelvic pain. J Am Assoc Gynecol Laparosc. Nov 1994;2(1):43-7. [Medline].
Kontoravdis A, Hassan E, Hassiakos D, Botsis D, Kontoravdis N, Creatsas G. Laparoscopic evaluation and management of chronic pelvic pain during adolescence. Clin Exp Obstet Gynecol. 1999;26(2):76-7. [Medline].
Williams TJ, Pratt JH. Endometriosis in 1,000 consecutive celiotomies: incidence and management. Am J Obstet Gynecol. Oct 1 1977;129(3):245-50. [Medline].
Cramer DW. Epidemiology of endometriosis. In: Wilson EA, ed. Endometriosis. New York, NY: Alan R. Liss; 1987:5-22.
Hadfield RM, Mardon HJ, Barlow DH, Kennedy SH. Endometriosis in monozygotic twins. Fertil Steril. Nov 1997;68(5):941-2. [Medline].
Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. Jun 1997;24(2):235-58. [Medline].
Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril. Jul 2000;74(1):24-30. [Medline].
Demco L. Mapping the source and character of pain due to endometriosis by patient-assisted laparoscopy. J Am Assoc Gynecol Laparosc. Aug 1998;5(3):241-5. [Medline].
Koninckx PR, Martin DC. Deep endometriosis: a consequence of infiltration or retraction or possibly adenomyosis externa?. Fertil Steril. Nov 1992;58(5):924-8. [Medline].
Koninckx PR, Oosterlynck D, D'Hooghe T, Meuleman C. Deeply infiltrating endometriosis is a disease whereas mild endometriosis could be considered a non-disease. Ann N Y Acad Sci. Sep 30 1994;734:333-41. [Medline].
Ferrero S, Esposito F, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Quality of sex life in women with endometriosis and deep dyspareunia. Fertil Steril. Mar 2005;83(3):573-9. [Medline].
Mounsey AL, Wilgus A, Slawson DC. Diagnosis and management of endometriosis. Am Fam Physician. Aug 15 2006;74(4):594-600. [Medline].
Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. Oct 2005;20(10):2698-704. [Medline].
Kingsberg SA, Janata JW. Female sexual disorders: assessment, diagnosis, and treatment. Urol Clin North Am. Nov 2007;34(4):497-506, v-vi. [Medline].
Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. May 1997;67(5):817-21. [Medline].
Hornstein MD, Gleason RE, Orav J, Haas ST, Friedman AJ, Rein MS, et al. The reproducibility of the revised American Fertility Society classification of endometriosis. Fertil Steril. May 1993;59(5):1015-21. [Medline].
Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril. Apr 1991;55(4):759-65. [Medline].
Barbati A, Cosmi EV, Spaziani R, Ventura R, Montanino G. Serum and peritoneal fluid CA-125 levels in patients with endometriosis. Fertil Steril. Mar 1994;61(3):438-42. [Medline].
Chen FP, Soong YK, Lee N, Lo SK. The use of serum CA-125 as a marker for endometriosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometriosis. Acta Obstet Gynecol Scand. Jul 1998;77(6):665-70. [Medline].
Yeaman GR, Collins JE, Lang GA. Autoantibody responses to carbohydrate epitopes in endometriosis. Ann N Y Acad Sci. Mar 2002;955:174-82; discussion 199-200, 396-406. [Medline].
Agic A, Djalali S, Wolfler MM, Halis G, Diedrich K, Hornung D. Combination of CCR1 mRNA, MCP1, and CA125 measurements in peripheral blood as a diagnostic test for endometriosis. Reprod Sci. Nov 2008;15(9):906-11. [Medline].
Mukund J. Sonography of adnexal masses. Ultrasound Clinics. January 2007;2(1):133-53.
Kinkel K, Chapron C, Balleyguier C, Fritel X, Dubuisson JB, Moreau JF. Magnetic resonance imaging characteristics of deep endometriosis. Hum Reprod. Apr 1999;14(4):1080-6. [Medline].
Takeuchi H, Kuwatsuru R, Kitade M, Sakurai A, Kikuchi I, Shimanuki H, et al. A novel technique using magnetic resonance imaging jelly for evaluation of rectovaginal endometriosis. Fertil Steril. Feb 2005;83(2):442-7. [Medline].
Sutton CJ, Pooley AS, Ewen SP, Haines P. Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertil Steril. Dec 1997;68(6):1070-4. [Medline].
Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril. Mar 1993;59(3):511-5. [Medline].
Reeve L, Lashen H, Pacey AA. Endometriosis affects sperm-endosalpingeal interactions. Hum Reprod. Feb 2005;20(2):448-51. [Medline].
Badawy SZ, ElBakry MM, Samuel F, Dizer M. Cumulative pregnancy rates in infertile women with endometriosis. J Reprod Med. Sep 1988;33(9):757-60. [Medline].
Marcoux S, Maheux R, Bérubé S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med. Jul 24 1997;337(4):217-22. [Medline].
Bukulmez O, Yarali H, Gurgan T. The presence and extent of endometriosis do not effect clinical pregnancy and implantation rates in patients undergoing intracytoplasmic sperm injection. Eur J Obstet Gynecol Reprod Biol. May 2001;96(1):102-7. [Medline].
Hughes E, Brown J, Collins JJ, Farquhar C, Fedorkow DM, Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst Rev. Jul 18 2007;CD000155. [Medline].
Benschop L, Farquhar C, van der Poel N, Heineman MJ. Interventions for women with endometrioma prior to assisted reproductive technology. Cochrane Database Syst Rev. Nov 10 2010;CD008571. [Medline].
Vercammen EE, D'Hooghe TM. Endometriosis and recurrent pregnancy loss. Semin Reprod Med. 2000;18(4):363-8. [Medline].
Allen C, Hopewell S, Prentice A, Gregory D. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. Apr 15 2009;CD004753. [Medline].
Nawathe A, Patwardhan S, Yates D, Harrison GR, Khan KS. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG. Jun 2008;115(7):818-22. [Medline].
Guzick DS, Huang LS, Broadman BA, Nealon M, Hornstein MD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril. Apr 2011;95(5):1568-73. [Medline].
Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. Sep 2004;191(3):733-40. [Medline].
Hull ME, Moghissi KS, Magyar DF, Hayes MF. Comparison of different treatment modalities of endometriosis in infertile women. Fertil Steril. Jan 1987;47(1):40-4. [Medline].
Kauppila A. Changing concepts of medical treatment of endometriosis. Acta Obstet Gynecol Scand. Jul 1993;72(5):324-36. [Medline].
Schlaff WD, Dugoff L, Damewood MD, Rock JA. Megestrol acetate for treatment of endometriosis. Obstet Gynecol. Apr 1990;75(4):646-8. [Medline].
Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol. Mar 1 2006;125(1):9-28. [Medline].
Anpalagan A, Condous G. Is there a role for use of levonorgestrel intrauterine system in women with chronic pelvic pain?. J Minim Invasive Gynecol. Nov-Dec 2008;15(6):663-6. [Medline].
Hughes E, Fedorkow D, Collins J, Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst Rev. 2000;CD000155. [Medline].
Winkel CA, Scialli AR. Medical and surgical therapies for pain associated with endometriosis. J Womens Health Gend Based Med. Mar 2001;10(2):137-62. [Medline].
Paoletti AM, Serra GG, Cagnacci A, Vacca AM, Guerriero S, Solla E, et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril. Apr 1996;65(4):707-10. [Medline].
Friedman AJ, Hornstein MD. Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain. Fertil Steril. Aug 1993;60(2):236-41. [Medline].
Taskin O, Yalcinoglu AI, Kucuk S, Uryan I, Buhur A, Burak F. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril. Jan 1997;67(1):40-5. [Medline].
Surrey ES, Voigt B, Fournet N, Judd HL. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy. Fertil Steril. Apr 1995;63(4):747-55. [Medline].
Lane N, Baptista J, Snow-Harter C. Bone mineral density of the lumbar spine in endometriosis subjects compared to an age-similar control population. J Clin Endocrinol Metab. Feb 1991;72(2):510-4. [Medline].
Surrey E, Hornstein M. Prolonged GnRH agonist add back therapy for symptomatic endometriosis patients: Long-term follow-up of a 12-month clinical trial. Fertil Steril. 1999;72:S80.
Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol. Jan 1999;93(1):51-8. [Medline].
Espaulella J, Armengol J, Bella F, Lain JM, Calaf J. Pulmonary endometriosis: conservative treatment with GnRH agonists. Obstet Gynecol. Sep 1991;78(3 Pt 2):535-7. [Medline].
Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. Dec 8 2010;CD008475. [Medline].
Telimaa S, Puolakka J, Rönnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol. Mar 1987;1(1):13-23. [Medline].
Dmowski WP, Kapetanakis E, Scommegna A. Variable effects of danazol on endometriosis at 4 low-dose levels. Obstet Gynecol. Apr 1982;59(4):408-15. [Medline].
Razzi S, Luisi S, Calonaci F, Altomare A, Bocchi C, Petraglia F. Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril. Oct 2007;88(4):789-94. [Medline].
Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev. Jan 21 2009;CD005997. [Medline].
Cook AS, Rock JA. The role of laparoscopy in the treatment of endometriosis. Fertil Steril. Apr 1991;55(4):663-80. [Medline].
Saidi MH, Vancaillie TG, White AJ, Sadler RK, Akright BD, Farhart SA. Complications of major operative laparoscopy. A review of 452 cases. J Reprod Med. Jul 1996;41(7):471-6. [Medline].
Revelli A, Modotti M, Ansaldi C, Massobrio M. Recurrent endometriosis: a review of biological and clinical aspects. Obstet Gynecol Surv. Oct 1995;50(10):747-54. [Medline].
Jones KD, Sutton C. Patient satisfaction and changes in pain scores after ablative laparoscopic surgery for stage III-IV endometriosis and endometriotic cysts. Fertil Steril. May 2003;79(5):1086-90. [Medline].
Beretta P, Franchi M, Ghezzi F, Busacca M, Zupi E, Bolis P. Randomized clinical trial of two laparoscopic treatments of endometriomas: cystectomy versus drainage and coagulation. Fertil Steril. Dec 1998;70(6):1176-80. [Medline].
Alborzi S, Momtahan M, Parsanezhad ME, Dehbashi S, Zolghadri J, Alborzi S. A prospective, randomized study comparing laparoscopic ovarian cystectomy versus fenestration and coagulation in patients with endometriomas. Fertil Steril. Dec 2004;82(6):1633-7. [Medline].
Donnez J, Nisolle M, Clerckx F. Evaluation of preoperative use of danazol, gestrinone, lynestrol, buserelin spray and buserelin implant, in the treatment of endometriosis related infertility. In: Chadha DR, Buttram VC Jr, eds. Current Concepts in Endometriosis. New York, NY: Alan R. Liss; 1990:427-42.
Vercellini P, Crosignani PG, Abbiati A, Somigliana E, Viganò P, Fedele L. The effect of surgery for symptomatic endometriosis: the other side of the story. Hum Reprod Update. Mar-Apr 2009;15(2):177-88. [Medline].
Johnson NP. A review of the use of lipiodol flushing for unexplained infertility. Treat Endocrinol. 2005;4(4):233-43. [Medline].
Wilson ML, Farquhar CM, Sinclair OJ, Johnson NP. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2000;CD001896. [Medline].
Proctor ML, Latthe PM, Farquhar CM, Khan KS, Johnson NP. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. Oct 19 2005;CD001896. [Medline].
Prentice A, Deary AJ, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2000;CD002122. [Medline].
Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2000;CD000346. [Medline].
Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2001;CD000068. [Medline].
Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2000;CD001019. [Medline].
Namnoum AB, Hickman TN, Goodman SB, Gehlbach DL, Rock JA. Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril. Nov 1995;64(5):898-902. [Medline].
Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril. Sep 1997;68(3):393-401. [Medline].
Society of Obstetricians and Gynaecologists of Canada. Canadian consensus conference on endometriosis consensus statements. J SOGC. 1999;21:471-3..
Redwine DB. Endometriosis persisting after castration: clinical characteristics and results of surgical management. Obstet Gynecol. Mar 1994;83(3):405-13. [Medline].
Hickman TN, Namnoum AB, Hinton EL, Zacur HA, Rock JA. Timing of estrogen replacement therapy following hysterectomy with oophorectomy for endometriosis. Obstet Gynecol. May 1998;91(5 Pt 1):673-7. [Medline].
Johnson KM. Endometriosis. The case for early, aggressive treatment. J Reprod Med. Mar 1998;43(3 Suppl):309-15. [Medline].
American College of Obstetricians and Gynecologists. Endometriosis in Adolescents. Committee Opinion. April 2005;Number 310:1-7.
Busacca M, Chiaffarino F, Candiani M, Vignali M, Bertulessi C, Oggioni G, et al. Determinants of long-term clinically detected recurrence rates of deep, ovarian, and pelvic endometriosis. Am J Obstet Gynecol. Aug 2006;195(2):426-32. [Medline].
Doyle JO, Missmer SA, Laufer MR. The effect of combined surgical-medical intervention on the progression of endometriosis in an adolescent and young adult population. J Pediatr Adolesc Gynecol. Aug 2009;22(4):257-63. [Medline].
Drosdzol A, Skrzypulec V. [Dysmenorrhea in pediatric and adolescent gynaecology]. Ginekol Pol. Jul 2008;79(7):499-503. [Medline].
Ferrero S, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Future perspectives in the medical treatment of endometriosis. Obstet Gynecol Surv. Dec 2005;60(12):817-26. [Medline].
Hummelshoj L, Prentice A, Groothuis P. Update on endometriosis. Women's Health. 2006;2(1):53-56.
Wayne PM, Kerr CE, Schnyer RN, Legedza AT, Savetsky-German J, Shields MH, et al. Japanese-style acupuncture for endometriosis-related pelvic pain in adolescents and young women: results of a randomized sham-controlled trial. J Pediatr Adolesc Gynecol. Oct 2008;21(5):247-57. [Medline]. [Full Text].
Print
